Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis
December 10th 2019CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.
Read More
Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status
December 9th 2019The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.
Read More
LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies
December 9th 2019More than half of patients with heavily pretreated B-cell malignancies responded to the noncovalent BTK inhibitor LOXO-305, including those with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors.
Read More
Adjuvant Immunotherapy Combinations on Horizon for Melanoma
November 8th 2019Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.
Read More
Novel Combinations Could Improve Cure Rates for Adult ALL
November 7th 2019Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.
Read More
Ripretinib Shows Dramatic PFS Improvement for Heavily Pretreated GIST
October 4th 2019Treatment with the novel KIT and PDGFRA inhibitor ripretinib reduced the risk of progression or death by 85% compared with placebo for heavily pretreated patients with advanced gastrointestinal stromal tumors, according to findings from the phase III INVICTUS trial presented at the ESMO Congress 2019.
Read More
Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC
September 30th 2019Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.
Read More
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
September 29th 2019The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.
Read More
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
September 29th 2019Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.
Read More
Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer
September 28th 2019Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.
Read More
Niraparib Improves PFS as Frontline Maintenance in Ovarian Cancer
September 28th 2019Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.
Read More
Frontline Veliparib Shows Intriguing PFS Findings in VELIA Trial
September 28th 2019The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.
Read More
New Therapies Intriguing for Elusive Targets in NSCLC
June 4th 2019Two new therapies are showing encouraging findings for patients with NSCLC with either RET rearranged or EGFR exon 20 insertions, raising hope that 2 hard-to-target driver alterations may soon have an associated targeted treatment.
Read More
Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial
June 3rd 2019A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.
Read More
Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer
June 1st 2019Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.
Read More
Treatment Tailoring Possible With Gene Expression Profiling
March 9th 2019Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.
Read More
Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL
December 4th 2018The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.
Read More